Can a japanese ARDS drug fix deadly clots in septic shock?

NCT ID NCT07214103

Not yet recruiting Disease control Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether sivelestat, a drug used in Japan for lung injury, can help restore the body's ability to break down harmful blood clots in people with septic shock. About 120 adults with septic shock and early blood clotting problems will receive either sivelestat or a placebo for 72 hours. The main goal is to see if sivelestat raises plasminogen levels, a key protein for dissolving clots.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sivelestat (a drug that blocks neutrophil elastase, given as a continuous IV infusion for 72 hours)
What this could lead to: If it works, this could point toward a new treatment to improve blood clot breakdown in septic shock patients, potentially reducing organ damage and death.
What could go wrong: This is an early Phase IIb trial with only 120 patients, so results may not be conclusive. The drug has not been proven for this specific condition, and risks like bleeding or allergic reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COAGULOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

blood coagulation disease disseminated intravascular coagulation toxic shock syndrome vascular hemostatic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COAGULOPATHY SEPTIC SHOCK

Contacts and locations

Locations

Hôpitaux Universitaires de Strasbourg

Strasbourg, France, 67091, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.